The primary goal of this study was to determine the 5`region of the Insl3 gene that specifically targets the expression of human insulin to Leydig cells, and to explore whether the testicular proinsulin is efficiently processed to insulin that is able to rescue the diabetes in different mouse models of diabetes. We show here that the sequence between nucleotides -690 to +4 of mouse Insl3 promoter is sufficient to direct the Leydig cell-specific expression of the human insulin transgene (Insl3-hIns). We also found that the 3´untranslated region (3´UTR) of Insl3 was effective in enhancing transgene expression of the insulin in vivo.
Introduction
Diabetes mellitus is a group of diseases characterised by an absolute or relative insulin deficiency and by poor glucose control (hyperglycemia) in the blood. In type I diabetes, also known as insulin-dependent diabetes mellitus (IDDM) or juvenile-onset diabetes mellitus, there is an absolute lack of insulin due to the progressive loss of pancreatic β-cells in the islets of Langerhans. Despite intensive research efforts, daily insulin injection remains the only therapy. This unsatisfactory treatment strongly affects the life style of the patients and cannot achieve the same degree of glycemic control as provided by endogenous insulin produced from the pancreatic β-cells. Therefore, transplantation of insulin-producing tissues and gene therapy are potential therapeutically strategies to overcome type I diabetes. Large-scale application of islet cell implantations to type I diabetic patients is hindered by limited availability of insulin-producing tissues and the subsequent need for life-long immunosuppressants (Remuzzi et al., 1994 ). An alternative approach is the ectopic expression of insulin in other tissues using gene therapy. The goal is to restore and to control insulin production in another tissue, thereby reducing the elevated blood glucose levels to a normal range without causing hypoglycemia. For successful therapy, at least three crucial issues must be adequately addressed. The ectopic tissues expressing engineered insulin must have constitutive and regulated secretory pathways and express proprotein convertases PC2 and PC1/3 that are required for proinsulin processing (Steiner, 1998) . These cells must have glucose sensing mechanisms for adequate regulation of insulin secretion according to blood glucose levels.
Several approaches, which have been taken in mind these crucial issues, have addressed the feasibility of in vivo gene therapy for the delivery of insulin to diabetic patients. Target tissues tested include liver, muscle, pituitary, exocrine pancreas and intestinal K-cells (Valera et al., 1994; Kolodka et al., 1995; Lipes et al., 1996; Goldfine et al., 1997; Bartlett et al., A c c e p t e d M a n u s c r i p t 4 1997; Abai et al., 1999; Bochan et al., 1999; Cheung et al., 2000; Lu et al., 2005) . The results are rather disappointing.
INSL3, a member of the insulin superfamily, is synthesized as preprotein in pre-and postnatal Leydig cells and play an essential role in growth of gubernaculums ligament during transabdominal descent of the testis (Zimmermann et al., 1997; Balvers et al., 1998; Nef and Parada, 1999; Adham et al., 2002; Koskimies et al., 2003) . Although the structure of circulating INSL3 is only known in bovine (Büllesbach and Schwabe, 2002) , the presence of certain conserved amino acids of the A and B chain at the N and C termini of the pro-INSL3
suggests that the mode of in vivo processing of pro-INSL3 and resulting structure of INSL3 is similar to that of insulin and relaxin (Adham et al., 1993; Hombach-Klonisch et al., 2004) . It is known that the processing of the proinsulin occurs in the trans-Golgi by a regulated secretory pathway (Kelly, 1985; Rhodes and Halban, 1987) . Similar to islet β cells, several endocrine cells such as intermediate lobe pituitary cells, and gastrointestinal G and K cells efficiently process proinsulin to mature, biologically active insulin via a regulated pathway of protein secretion (Lipes et al. 1996 , Cheung et al., 2000 Lu et al., 2005) , whereas in hepatocytes, which have only a constitutive pathway of protein secretion, proinsulin processing to insulin is extremely inefficient (Valera et al., 1994; Kolodka et al., 1995) .
To assess the efficiency of the endocrine Leydig cells in processing the proinsulin to the biological active insulin and to determine the ability of the testicular insulin to overcome the diabetes in mice, we overexpressed insulin in the Leydig cells during pre-and postnatal development. The rational for this study was underpinned by our previous study showing that ectopic expression of Insl3 in β-cells rescue the cryptorchidism in Insl3-null males. These results reveal that the β-cells efficiently processed the Insl3 gene product to the functional hormone. To achieve our goal, the insulin was targeted using the upstream regulated sequence of murine Insl3 gene, and transgenic mice were generated. To determine whether the Page 5 of 27 A c c e p t e d M a n u s c r i p t 5 testicular insulin would rescue diabetes observed in the Pax-4 deficient mice, we introduced the transgenic allele into the Pax-4 -/-mice.
Materials and Methods

Generation of transgenic mice
The 0.7-kb HindIII/XbaI fragment containing the 5´flanking region of mouse Insl3 was isolated from the p690-CAT plasmid (Zimmermann et al., 1998) and subclond into pBluescript IIKS+ (Stratagen) to produce pInsl3. To generate the Insl3-hIns/1 construct, a 1.7-kb genomic fragment containing exons 1-3 of human insulin gene (hIns) was amplified using the primers Hins2F: 5´-GCC GCT CTA GAC CTG AGC CCT CCA GGA CAG -3´and
Hins2R: 5´-GCC GCG CGG CCG CGG GAG GGG CTC ACA ACA GTG C -3´. The 1.7-kb amplified fragment with an artificial XbaI site at 5´-end and a NotI site at 3´-end was inserted into the XbaI/NotI-digested pInsl3 to create Insl3-hIns/1 construct. A 1.3-kb XbaI/NotI fragment containing the genomic sequence of hIns without the 3´untranslated region was amplified using the primers Hins2F and Hins11R: 5-GCC GCG CGG CCG CCC TGC AGG CTG CGT CTA GTT -3´and subcloned into pInsl3 to create the pInsl3-hIns∆3´. Finally, a 250-bp NotI/SstII genomic fragment containing the 3´untranslated region of mouse Insl3 was amplified using the primers Minsl1F: 5´-GCC GCG CGG CCG CTG AAG GAG CAC AGG GCT CAG G -3´and Minsl1R: 5´-GCC GCC CGC GGC GGT CTG GTC CGT GTG TGA ).
The following primers were used to discriminate between wild-type and mutant Pax4 alleles.
Primers Pax 4F: 5´ ATG GCT GTG TGA GCA AGA TCC -3´and primer Pax 4R: 5´-TCC AGC TTC CCT TAA CTC CAG -3´ were designed to amplify a 250-bp fragment of wildtype allele. The primer LacZ-F. 5´-TTG GCG TAA GTG AAG CGA C -3´ was used with the primer LacZ-R: 5´-AGC GGC TGA TGT TGA ACT G -3´ to amplify a 500-bp fragment of mutant Pax4 allele.
RNA analysis
Different tissues were dissected out from 3-month-old wild-type and transgenic mice or from testes of 1-, 3-, 5-, 6-, 8-, 10-, 15-, 20-, and 25-d-old RT-PCR assays were performed using 2 µg of total RNA and a One
Step RT-PCR kit (QIAGEN). Primers to amplify the PC1 cDNA fragment were 5'-TCA ACC AGA GCA CAT GAA GC -3' and 5'-GCA GCA GCC TGT CAT CTC TA -3', and those to amplify the PC2 transcript were 5'-ATG GAG GGC GGT TGT GGA TC -3' and 5'-CAG GTA CCA TTG CTT TGT AAA GAG A -3'.
Immunohistochemistry
Testis and pancreas from wild-type and Insl3-hIns transgenic mice were fixed in Bouin's fixative and transferred to 70% ethanol before paraffin embedding. Sections (5µm) were cut from paraffin blocks with a rotary microtome and mounted on SuperFrost Plus glass slides (Fisher Scientific, Nepean, Canada). Sections were deparaffinized in xylene, rehydrated in a descending alcohol. Thereafter, tissue sections were preincubated for 1 h with 10% normal horse serum in 2% Tween/PBS and incubated overnight at 4°C with 1:500 mouse monoclonal anti-insulin antibody (Sigma, St. Luis, USA), washed in PBS, and then incubated with CY3-conjugated goat anti-mouse antibody (1:500) (Sigma) for 30 min at room temperature. Slides were then washed in PBS, stained with DAPI (Vector), and examined with a BX60 microscope (Olympus, Hamburg, Germany) with fluorescence equipment and an analysis software program (Soft Imaging System, Münster, Germany).
Measurement of proinsulin and C-peptide level in protein extracts and serum
To determine pancreatic and testicular proinsulin content, whole pancreas and testis was removed from the mice, weighted, and homogenized in 20 vol of cold acidic ethanol (75% ethanol, 1.5% concentrated HCl) followed by 48 h of agitation at 4°C. Thereafter, insulin was quantified in the supernatants of the samples by time-resolved fluoroimmunoasssay. Insulin Serum C-peptide was determined by radioimmunoassay (RIA) (Linco Research, St. Charles, USA) following the manufacturer's instructions, using specific 125 I-labelled human C-peptide as tracer and a human C-peptide antibody. Antibody was 100% crossreactive with human Cpeptide and < 4% crossreactive with human proinsulin (Sensitivity of 0.1 ng/ml).
Generation of diabetic mice
To induce insulin-dependent diabetes, 2-month-old male mice were injected intraperitoneally with streptozotocin (STZ) (Sigma, Munich, Germany) (33.3 mg/kg body weight), dissolved in 50 mmol/l citrate buffer (pH 4.5) for 5 consecutive days. Blood glucose was determined four times a week in blood obtained from the tail vein using a HeamoglucoTest glucometer (Roche Molecular Biochemicals, Mannheim, Germany). Mice were considered diabetic after two consecutive blood glucose values of more than 250 mg/dl.
For glucose tolerance tests, STZ-treated transgenic and non-treated wild-type mice were fasted overnight with free access to water and thereafter injected intraperitoneally with glucose (1 mg/kg body weight). Blood samples were obtained from the tail vein before the glucose injection and at 20, 40, and 60 min after injection, and the glucose concentration was measured as indicated above.
Fertility test and sperm parameters
To investigate the fertility of the transgenic males on a FVB/N background, 3-month-old male mice were mated each with two wild-type FVB/N females. Females were checked for the presence of vaginal plug and/or pregnancy. Pregnant females were removed to holding cages to give birth. Litter size sired by each group of males was determined after 4-, 8-and 12-months of breeding.
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The epididymides from transgenic male mice were collected and dissected in IVF medium.
Sperm number in the cauda epididymis was determined using a Neubauer counting cell chamber. Motility was analysed by a CEROS computer-assisted semen analysis system (version 10; Hamilton Thorne Research, Beverly, Mass).
Statistical analysis
All results are presented as the means ± SD (SEM). The significance of differences was assessed using the Student´s t test. Differences were considered significant at p < 0.05.
Results
Generation of Insl3-hIns transgenic mice
Analyses of the mouse Insl3 promoter in vitro predicted that the proximal region of Insl3 promoter might be sufficient for targeted expression of reporter gene in Leydig cells (Zimmermann et al., 1998; Koskimies et al., 2002) . To determine the regulatory sequences of Insl3, which are required for Leydig cell-specific expression of reporter gene in vivo and for stability of transgenic RNA in Leydig cells, two transgenic constructs were designed using the 5´ flanking region of Insl3 (-690 to +4) fused to the human insulin gene (hIns). In the first construct (Insl3-hIns/1), the three exons of hIns including the 3´untranslated region were ligated downstream of 5´regulatory sequence of Insl3. In the second construct (Insl3-hIns/2), the 3´untranslated sequence of hIns was replaced with that of mouse Insl3 (Fig. 1A) . Both fusion constructs were microinjected into the pronuclei of fertilized FVB/N mouse eggs. Four and five transgenic founders were found to carry the Insl3-hIns/1 and the Insl3-hIns/2 fusion allele, respectively, as detected by PCR assay using specific primers (data not shown).
Transgenic mice were maintained as hemizygotes and mated to wild-type FVB/N for further analyses.
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Expression analysis of transgenic insulin in Leydig cells
To determine whether the Insl3-INS transgenic alleles are transcriptional active, Northern blots containing total RNA extracted from testes of F1-animals of four transgenic Insl3-INS/1 and five transgenic Insl3-hIns/2 founders were hybridized with the hIns cDNA probe. As shown in figure 1B , the expression of Insl3-hIns/1 transgenic allele was only detectable at low level in testis of line #4. In contrast, high levels of hIns mRNA were found in testes of four To determine the extent of transgene expression, we performed Northern blot analysis of various tissues from hemizygous offspring of line #5 using a hIns cDNA probe. A transcript of the expected size (0.7-kb) was observed in testis of transgene, but not in other tissues (Fig.   1C ).
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The temporal regulation of the hIns-transgene expression was analyzed by Northern blot with testicular RNA from sequential time points of postnatal development. During the first three weeks of testis development, equal levels of the transgene transcript were observed. The
Insl3 expression was also determined from the same blot using an Insl3 cDNA probe. After three weeks of postnatal testis development, the hIns mRNA level gradually increased,
showing an expression pattern roughly similar to that of the endogenous Insl3 mRNA (Fig.   1D ).
The distribution of hINS protein in the testis was determined by using monoclonal antibody to human insulin. In testis sections of transgenic mice, insulin immunoreactivity was detected in Leydig cells, confirming that human insulin protein production was specifically targeted to Leydig cells (Fig. 1E) . Results of these expression experiments provide evidence that the sequence -690 to +4 of the 5´flanking region of Insl3 directs in vivo the transcription of reporter gene in Leydig cells but not in other tissues, indicating that the cis-acting elements of Leydig cell-specific expression reside within this region.
Leydig cells translate and process proinsulin
To determine the translation rate of the transgene, proinsulin content was measured in testes and pancreas of fasted wild-type and transgenic males (> 8-week-old) by a fluoroimmunoassay, which specifically recognizes the human and mouse form of proinsulin As shown in figure 2A , proinsulin levels in testicular extracts of transgenic mice (10.75 ± 0.99 µU/mg, n = 13) were not significantly different from that in pancreas of wild-type (11.6 ± 1.34 µU/mg, n = 6) and transgenic pancreas (12.23 ± 1.08 µU/mg, n = 13). Similar concentrations of proinsulin were found in transgenic and control pancreas. In contrast, only basal level of proinsulin was detected in wild-type testis ( Fig. 2A) . These results suggest that the human proinsulin produced by transgenic allele do not alter the expression of endogenous insulin production in the pancreas.
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To determine the testicular expression of prohormone convertases PC2 and PC1/3 that process the proinsulin to insulin, we performed RT-PCR analysis. This analysis revealed the expression of PC1 and PC1/3 in testicular Leydig cells (data not shown).
Whether testicular proinsulin is processed to insulin which is secreted into serum, free human C-peptide in serum of fasted wild-type and transgenic males was measured with Cpeptide-specific immunoassay that has no cross-reactivity with mouse insulin or human proinsulin. The levels of human C-peptide in samples collected from individual mice of transgenic line #5 and #9 was 0.51 ± 0.45 ng/ml (n = 11) and 0.43 ± 0.41 ng/ml (n = 11), respectively, whereas serum C-peptide levels in wild-type males were below the detection limits of radioimmunoassay (Fig. 2B) . However, the C-peptide levels in serum of both transgenic lines were lower than the normal level of C-peptide in human serum (0.5-4.0 ng/ml). The presence of human C-peptide in serum of transgenic males indicates that the Leydig cell-produced proinsulin is processed to insulin, and secreted into the serum.
However, transgenic mice display normal blood glucose levels whether fed or fasted (Fig.   2C ). The body weights of transgenic males at the age of 3-and 6-months were indistinguishable from those of their control littermates (Fig. 2D) .
Testicular insulin can not rescue the diabetic Pax-4 deficient mice
We have then investigated the efficiency of Leydig cell-derived human insulin to rescue A c c e p t e d M a n u s c r i p t 13 (220.3 ± 12.2 versus 242 ± 9.3, n = 6 in each group), but were significantly higher than that in wild-type littermates (120.3 ± 4.6, n = 6). These results indicate that testicular INS was not able to overcome the diabetes resulting from the impaired development of pancreatic β-cells in Pax4 -/-mice.
Leydig cells lack the glucose sensing mechanism
The insufficiency of testicular insulin to rescue the Pax4 -/-neonates from diabetes may be due to impairment of Leydig cells to secret high levels of human insulin in response to increase of blood glucose levels. Therefore, we examined whether insulin production from
Leydig cells was able to maintain glucose tolerance in the transgenic animals. Streptozotocin (STZ), a β-cell toxin, was administered to transgenic and wild-type mice. In both transgenic and wild-type animals, STZ-treatment resulted in hyperglycemia (Fig. 2E) were then intraperitoneally injected with glucose. Blood glucose levels were dramatically decreased in control animals at 40 and 60 min after injection. In contrast, the human insulin produced from Leydig cells of transgenic mice was not sufficient to restore normal glucose tolerance (Fig. 2F ).
Progressive loss of germ cells in the Insl3-hIns-transgenic testis
To identify and establish homozygous transgenic mice, 10 transgenic males and females from F2 generation were crossed with wild-type mice. Genotyping of offspring from these breeding revealed that all homozygous transgenic females of line #5 and #9 are fertile. In Breeding of hemizygous transgenic males with wild-type mice revealed that the fertility of transgenic males at 4-months-old did not significantly differ from that of controls. However, the litter size produced by transgenic males declined with advancing age (Table 1) . We noticed a large variability in the age on onset of infertility among transgenic mice. Some mice were initially fertile but developed infertility later on.
To investigate the underlying cause of reproductive defects in transgenic males, sperm parameters were analyzed in great detail. As shown in Table 1 , significant reduction in the mean number of spermatozoa and the proportion of motile and progressively motile sperm collected from the cauda epididymides of 8-and 12-months-old transgenic mice (p < 0.001).
Next, we investigated potential pathologic alterations in testes of 4-, 8-and 12-months-old transgenic mice. At 4-months-old, there were no gross morphological differences between wild-type and transgenic seminiferous tubules (Fig. 3A, B) . Transgenic testes from 8-monthold revealed a mixed atrophy type of damage showing seminiferous tubules with apparently normal spermatogenesis, tubules with focally degenerated germ cells or tubules with almost complete loss of spermatogenic cells. Often damaged tubules contained vacuoles. Overall, a large variability in the degree of testicular degeneration was observed within one tubule crosssection, amongst neighbouring tubules and amongst testes of different transgenic mice at this age (Fig. 3C) . During the next months, the phenotype becomes more pronounced. In testes of 12-months-old transgenic mice, about 85% of all seminiferous tubules displayed severe impairment of spermatogenesis with severe vacuolization of most affected tubules (Fig. 3D ).
To determine whether the germ cell loss in transgenic testis resulted from increased germ cell A c c e p t e d M a n u s c r i p t 15 apoptosis, we used TUNEL assay to detect apoptotic cells in 4-and 8-months-old wild-type and transgenic testis. In transgenic testis, we observed only a few apoptotic cells, and the number and position of these cells were similar to those of wild-type, indicating that the degeneration of spermatogenic cells is not due to increased germ cell apoptosis (data not shown). Therefore, the observed phenotype may be caused by impairment of early germ cell proliferation or differentiation rather than by a specific arrest during spermatogenesis.
Discussion
Previous cell culture experiments have shown that the sequence from -690 to +4 of Insl3 gene was able to direct expression of reporter constructs in Leydig cell lines (Zimmermann et al., 1998; Koskimies et al., 2002) . In order to determine whether this part of the promoter is also sufficient in vivo to direct tissue-and cell-specific expression, transgenic mice were generated. The transgene Insl3-hIns/1 contains the sequence between -690 to +4 of Insl3 promoter cloned upstream of the human insulin gene as reporter. The data show that this transgenic allele is expressed at low levels in all four generated lines. The results of many studies showed that the 3´-untranslated region of a gene influences the stability of its mRNA (Ross, 1995; Kakoki et al., 2004) . Based on these results, we replaced the 3´untranslated region of human insulin gene with that of mouse Insl3 in the second construct Insl3-hIns/2.
Four of five Insl3-hIns/2 transgenic lines showed significantly higher transgene expression than those in testes of Insl3-hIns/1 transgenic lines, despite the presence of comparable copy number of both transgenic alleles. These results suggest that the 3´-untranslated region of Insl3 contains elements, which are responsible for stability of transgenic transcripts in Leydig cells. Just as endogenous Insl3 expression, expression of transgenic Insl3-hIns/2 allele is restricted to Leydig cells and expression level is constant through the first three weeks of postnatal testis development and increases gradually thereafter. Thus, the promoter and the M a n u s c r i p t 16 3´untranslated region of Insl3, which we have characterized here, will provide a useful tool to direct the specific expression of genes to Leydig cells in vivo.
We next explored whether the testicular proinsulin is efficiency processed to insulin which is able to rescue the diabetes in Pax-4 -/-mice. The in vivo data revealed that proinsulin content of transgenic testes was not significantly different from that of wild-type pancreas. The presence of a significant amount of immunoreactive free human C-peptide in serum of transgenic mice suggests that the ectopically produced insulin is secreted in the circulation.
However, the testis-derived insulin is not able to reverse diabetic symptoms in Pax4-deficient mice. Endogenous insulin expression and secretion in pancreatic β-cells is regulated by glucose, so that insulin will be produced and released in response to rise in blood glucose levels and is suppressed as blood glucose concentration decline. Results of glucose tolerance experiments revealed that a major limitation of this current gene delivery system is that the insulin secretion in the Leydig cells is not glucose regulated. A number of studies has engineered a variety of cells and tissues to produce insulin in transgenic mice. Lack of the glucose sensing mechanisms in target tissues, including liver, pituitary, muscle and exocrine pancreas, limit the clinical application of these approaches (Kolodka et al., 1995; Lipes et al., 1196; Goldfine et al., 1997; Bartlett et al., 1997; Abai et al., 1999; Valera et al., 1994; Bochan et al., 1999) . In contrast, transgenic mice producing human proinsulin under the control of the K-cell specific GIP promoter have been shown to produce mature bioactive insulin in a glucose concentration-dependent manner (Cheung et al., 2000) .
Insulin signalling is important for promoting and regulating of growth, differentiation, and metabolism. Disruption of components of the insulin-signaling pathway can result in infertility (Rane et al., 2000; Brüning et al., 2000) . Reduced secretion of LH and FSH in diabetic men and in conditional knockout mice, which lack the insulin receptor (IR) in brain, revealed that insulin play a central role in regulation of hypothalamic pituitary testicular axis (Brüning et al., 2000; Baccetti et al., 2002) . Impaired spermatogenesis of diabetic men was (Oyadomari et al., 2002) . Therefore, we suggest that the overload of Leydig cells with proinsulin may be deleterious for Leydig cell function.
Dysregulation of stroidogenesis in transgenic males could be perturbed and that could explain the disruption observed on spermatogenesis yield and sperm motility. Alternatively, the Leydig cell-producing insulin has autocrine effects that negatively influence germ and Sertoli cell survival. Page 27 of 27 A c c e p t e d M a n u s c r i p Figure 3 
